Viddler

pffoundation

pffoundation

PFF Hill Day 2024 Training PFF Hill Day 2024 Training
Hill Day Training 2022_v3 Hill Day Training 2022_v3
Virtual Support Group Zoom Basics Training Virtual Support Group Zoom Basics Training
Life with PF - Gary and Marianne Life with PF - Gary and Marianne
Hill Day 2020 Prep Teleconference Hill Day 2020 Prep Teleconference
2019-12-20 14.39 Review Dark Matter Platform 2019-12-20 14.39 Review Dark Matter Platform
AskADoc_June2019 AskADoc_June2019
Support Group Advocacy Training Support Group Advocacy Training
Advance Directives_April2019 Advance Directives_April2019
PF and Mental Health_Feb2019 PF and Mental Health_Feb2019
Exposure-RelatedPF_013019 Exposure-RelatedPF_013019
CTD-ILD_Dec 2018 CTD-ILD_Dec 2018
The Diagnostic Process for PF_Oct 2018 The Diagnostic Process for PF_Oct 2018
FDA's Drug Approval Process_September2018 FDA's Drug Approval Process_September2018
PF Myths Debunked_August2018 PF Myths Debunked_August2018
advocacyAug18 advocacyAug18
researchupdate2018 researchupdate2018
Non-Genetic Causes of PF_April2018 Non-Genetic Causes of PF_April2018
Lung Transplantation_March 2018 Lung Transplantation_March 2018
AskADoc_January2018 AskADoc_January2018
Patient Assistance Programs-IPFTherapies_December 2017 Patient Assistance Programs-IPFTherapies_December 2017
Summit Prep Teleconference_2017 Summit Prep Teleconference_2017
PFF Daughters Teleconference_10.27.17 PFF Daughters Teleconference_10.27.17
PFF Disease Education Webinar_Clinical Trials Overview September 2017 PFF Disease Education Webinar_Clinical Trials Overview September 2017
PFF Disease Education Webinar_Nutrition and ILD August 2017 PFF Disease Education Webinar_Nutrition and ILD August 2017
August 2017 SGLN Teleconference August 2017 SGLN Teleconference
PFF Ambassador_August 2017 Teleconference PFF Ambassador_August 2017 Teleconference
PFF Ambassador Teleconference July 2017 PFF Ambassador Teleconference July 2017
PFF Disease Education Webinar_Familial ILD and Genetics_July 2017 PFF Disease Education Webinar_Familial ILD and Genetics_July 2017
Ask a Doc Webinar_June2017 Ask a Doc Webinar_June2017
PFF Ambassador Teleconference_6.14.17 PFF Ambassador Teleconference_6.14.17
SGLN Teleconference_5.8.17 SGLN Teleconference_5.8.17
PFF Daughters Quarterly Tele_4.28.17 PFF Daughters Quarterly Tele_4.28.17
PFF Hill Day 2017 Prep Tele PFF Hill Day 2017 Prep Tele
Caregiving Webinar April 2017 Caregiving Webinar April 2017
PFF Ambassador Teleconference_3.15.17 PFF Ambassador Teleconference_3.15.17
Untitled Untitled
2017-02-21 14.10 PFF SGLN Teleconference 2017-02-21 14.10 PFF SGLN Teleconference
Hypersensitivity Pneumonitis_2.15.17 Hypersensitivity Pneumonitis_2.15.17
PFF Ambassador Teleconference_Jan17 PFF Ambassador Teleconference_Jan17
PFF Daughters Quarterly Teleconference_1.28.17 PFF Daughters Quarterly Teleconference_1.28.17
Anti-Inflammatory & Immunosuppressive Medications Anti-Inflammatory & Immunosuppressive Medications
Jordan Howard Ad in Times Square Jordan Howard Ad in Times Square
December Teleconference December Teleconference
SGLN Teleconference December 2016 SGLN Teleconference December 2016
PFF Ambassador Orientation_11.3.16 PFF Ambassador Orientation_11.3.16
Annual Vol Mtg_11.2.16 Annual Vol Mtg_11.2.16
October Teleconference October Teleconference
What is PF? Webinar-Arabic_09.7.16 What is PF? Webinar-Arabic_09.7.16
What Is PF? Webinar-Vietnamese_9.7.16 What Is PF? Webinar-Vietnamese_9.7.16
What Is PF? Webinar-Urdu_9.7.16 What Is PF? Webinar-Urdu_9.7.16
What Is PF? Webinar-Spanish_9.7.16 What Is PF? Webinar-Spanish_9.7.16
What Is PF? Webinar-Russian_9.7.16 What Is PF? Webinar-Russian_9.7.16
What is PF Webinar-Mandarin_9.7.16 What is PF Webinar-Mandarin_9.7.16
What Is PF? Webinar-Hindi_9.7.16 What Is PF? Webinar-Hindi_9.7.16
What Is PF? Webinar-English_9.7.16 What Is PF? Webinar-English_9.7.16
What Is PF? -Polish_9.7.16 What Is PF? -Polish_9.7.16
PFProgression Webinar_10.12.16 PFProgression Webinar_10.12.16
SGLN Teleconference August 2016 SGLN Teleconference August 2016
PFF Ambassador Teleconference_8.10.16 PFF Ambassador Teleconference_8.10.16
IPF PSA 60-Second FINAL IPF PSA 60-Second FINAL
PFF Daughters Steering Co Meeting_7.14.16 PFF Daughters Steering Co Meeting_7.14.16
ExercisePulmonaryRehab_7.13.2016 ExercisePulmonaryRehab_7.13.2016
PFF SGLN Teleconference_6.27.16 PFF SGLN Teleconference_6.27.16
Sirius XM Doctor Radio - Dr Glassberg 6-16-16 Sirius XM Doctor Radio - Dr Glassberg 6-16-16
Ambassador Teleconference_6.21.16 Ambassador Teleconference_6.21.16
Daughters Steering Co Teleconference_6.7.16 Daughters Steering Co Teleconference_6.7.16
Ambassador Teleconference_May 2016 Ambassador Teleconference_May 2016
Ambassador Teleconference_May 2016 Ambassador Teleconference_May 2016
OxygenEquipmentOverview_5.11.16 OxygenEquipmentOverview_5.11.16
7619791_USARADIO_AC 7619791_USARADIO_AC
7619791_ProjectHealth_AC 7619791_ProjectHealth_AC
UpdatePFResearchCCNRegistry_April2016FINAL UpdatePFResearchCCNRegistry_April2016FINAL
SGLN Teleconference_3.21.16 SGLN Teleconference_3.21.16
AskADocGERDSleepApnea31616 AskADocGERDSleepApnea31616
SGLN Training Webinar III SGLN Training Webinar III
Plenary Session and Panel Discussion: Leveraging the PFF Care Center Network | Leaders: Vincent Cottin, MD, PhD; Kevin R. Flaherty, MD, MS; Jesse Roman, MD Plenary Session and Panel Discussion: Leveraging the PFF Care Center Network | Leaders: Vincent Cottin, MD, PhD; Kevin R. Flaherty, MD, MS; Jesse Roman, MD
Julie_Halston_Broadway16_30sec Julie_Halston_Broadway16_30sec
Fibrosis as a Disease of Aging and Mitochondrial Dysfunction | Ana L. Mora, MD Fibrosis as a Disease of Aging and Mitochondrial Dysfunction | Ana L. Mora, MD
Integrating Biomarkers in Clinical Studies to Affect Patient Care | Fernando J. Martinez, MD, MS Integrating Biomarkers in Clinical Studies to Affect Patient Care | Fernando J. Martinez, MD, MS
Molecular and Cellular Biomarkers of Pulmonary Fibrosis | Naftali Kaminski, MD Molecular and Cellular Biomarkers of Pulmonary Fibrosis | Naftali Kaminski, MD
Mechanotransduction and the Role of Tissue Stiffness in Fibrosis | Mitchell Olman, MA, MD Mechanotransduction and the Role of Tissue Stiffness in Fibrosis | Mitchell Olman, MA, MD
Understanding PFTs_December 2015_2 Understanding PFTs_December 2015_2
Palliative and Advanced Care | Susan S. Jacobs, RN, MS Palliative and Advanced Care | Susan S. Jacobs, RN, MS
Question-and-Answer Period and Panel Discussion | Leader: Joseph A. Lasky, MD Question-and-Answer Period and Panel Discussion | Leader: Joseph A. Lasky, MD
Clinical Trials in the Era of Effective Therapies | Luca Richeldi, MD, PhD Clinical Trials in the Era of Effective Therapies | Luca Richeldi, MD, PhD
The Promise of Registries | Christopher J. Ryerson, MD The Promise of Registries | Christopher J. Ryerson, MD
PFF Patient Survey Results | Gregory P. Cosgrove, MD, FCCP PFF Patient Survey Results | Gregory P. Cosgrove, MD, FCCP
Patient Perspective: Living Well with Pulmonary Fibrosis | Charolette Saunders Patient Perspective: Living Well with Pulmonary Fibrosis | Charolette Saunders
patient_saturday_1145_Panel_C-Summit-2015 patient_saturday_1145_Panel_C-Summit-2015
Symptom Management | Maryl E. Kreider, MD, MSCE Symptom Management | Maryl E. Kreider, MD, MSCE
Lung Transplantation | Steven D. Nathan, MD, FCCP Lung Transplantation | Steven D. Nathan, MD, FCCP
patient_friday_1530_Courtney-Summit-2015 patient_friday_1530_Courtney-Summit-2015
Question-and-Answer Period and Panel Discussion | Leader: Marilyn K. Glassberg, MD Question-and-Answer Period and Panel Discussion | Leader: Marilyn K. Glassberg, MD
Managing Comorbidity | Vincent Cottin, MD, PhD Managing Comorbidity | Vincent Cottin, MD, PhD
Pulmonary Rehabilitation and Oxygen Therapy | Anne E. Holland, PhD Pulmonary Rehabilitation and Oxygen Therapy | Anne E. Holland, PhD
Pharmacologic Therapy | Charlene D. Fell, MD, MSc Pharmacologic Therapy | Charlene D. Fell, MD, MSc
Patient Perspective: Living Well with Pulmonary Fibrosis | Pete Mulliner Patient Perspective: Living Well with Pulmonary Fibrosis | Pete Mulliner
Question-and-Answer Period and Panel Discussion | Leader: Joao Alberto M. de Andrade, MD Question-and-Answer Period and Panel Discussion | Leader: Joao Alberto M. de Andrade, MD
Communicating Prognosis and Goals of Care | Sonye K. Danoff, MD, PhD Communicating Prognosis and Goals of Care | Sonye K. Danoff, MD, PhD
Diagnosing the Cause of Pulmonary Fibrosis | Kevin F. Gibson, MD Diagnosing the Cause of Pulmonary Fibrosis | Kevin F. Gibson, MD
What is Pulmonary Fibrosis and Why is it a Problem? | Joyce Lee, MD What is Pulmonary Fibrosis and Why is it a Problem? | Joyce Lee, MD
SGLN Training Webinar Session II_12.14.15 SGLN Training Webinar Session II_12.14.15
professional_Saturday_0830_Panel-Summit-2015 professional_Saturday_0830_Panel-Summit-2015
professional_Saturday_0830_Panel-Summit-2015 professional_Saturday_0830_Panel-Summit-2015
Plenary Session and Panel Discussion - The Future of Clinical Trials in Pulmonary Fibrosis | Leaders: David J. Lederer, MD, MS; Kevin K. Brown, MD Plenary Session and Panel Discussion - The Future of Clinical Trials in Pulmonary Fibrosis | Leaders: David J. Lederer, MD, MS; Kevin K. Brown, MD
Case Presentation I | Abigail R. Lara, MD Case Presentation I | Abigail R. Lara, MD
Case Presentation III | Andrew Youn, MD, FRCPC Case Presentation III | Andrew Youn, MD, FRCPC
Case Presentation II | Brett J. Ley, MD Case Presentation II | Brett J. Ley, MD
Presentation: How to Organize MDD in the Real World | Charlene D. Fell, MD, MSc Presentation: How to Organize MDD in the Real World | Charlene D. Fell, MD, MSc
Discussion Discussion
Palliative Care and Hospice: Losing or Retaking Control? | Kathleen O. Lindell, RN, PhD Palliative Care and Hospice: Losing or Retaking Control? | Kathleen O. Lindell, RN, PhD
Lung Transplantation: Nuts and Bolts or…This is Nuts, I am Going to Bolt | David J. Lederer, MD, MS Lung Transplantation: Nuts and Bolts or…This is Nuts, I am Going to Bolt | David J. Lederer, MD, MS
Towards an Improved Quality of Life: Starring Oxygen Therapy and Pulmonary Rehab | Anne E. Holland, PhD Towards an Improved Quality of Life: Starring Oxygen Therapy and Pulmonary Rehab | Anne E. Holland, PhD
5th Place: Renea Jablonski, SIRT3, the anti-aging major mitochondrial deacetylase, is important for preventing pulmonary fibrosis 5th Place: Renea Jablonski, SIRT3, the anti-aging major mitochondrial deacetylase, is important for preventing pulmonary fibrosis
Precision Medicine for IPF: Dream or Reality? | Imre Noth, MD Precision Medicine for IPF: Dream or Reality? | Imre Noth, MD
Novel Targets for the Future: What’s Promising? | Andrew M. Tager, MD Novel Targets for the Future: What’s Promising? | Andrew M. Tager, MD
Approved Drugs for IPF: Should They be Studied for Non-IPF Pulmonary Fibrosis? | Kevin K. Brown, MD Approved Drugs for IPF: Should They be Studied for Non-IPF Pulmonary Fibrosis? | Kevin K. Brown, MD
Clinical Topic I - Session Leader Introduction | Luca Richeldi, MD, PhD Clinical Topic I - Session Leader Introduction | Luca Richeldi, MD, PhD
4th Place: Louise Hecker, Impaired Myofibroblast Dedifferentiation Contributes to Non-Resolving Fibrosis in Aging 4th Place: Louise Hecker, Impaired Myofibroblast Dedifferentiation Contributes to Non-Resolving Fibrosis in Aging
Collaborative Networks as Tools for Improving Clinical Care | Pat Furlong Collaborative Networks as Tools for Improving Clinical Care | Pat Furlong
Panel Discussion Panel Discussion
Patient-Centered Research: PCORI and the Patient Voice | Sonye K. Danoff, MD, PhD Patient-Centered Research: PCORI and the Patient Voice | Sonye K. Danoff, MD, PhD
Measuring Function: Beyond the 6MWT | Amy L. Olson, MD Measuring Function: Beyond the 6MWT | Amy L. Olson, MD
How to Build a Patient-Reported Outcome (PRO) | Hilary Wilson, PhD How to Build a Patient-Reported Outcome (PRO) | Hilary Wilson, PhD
3rd Place: Rachel Scheraga, The mechanosensitive transient receptor potential vanilloid 4 (TRPV4) ion channel mediates the pro-resolution/anti-fibrotic macrophage response to endotoxin (LPS) 3rd Place: Rachel Scheraga, The mechanosensitive transient receptor potential vanilloid 4 (TRPV4) ion channel mediates the pro-resolution/anti-fibrotic macrophage response to endotoxin (LPS)
Discussion, Session Overview, and Close | Andrew M. Tager, MD Discussion, Session Overview, and Close | Andrew M. Tager, MD
The Role of Macrophages in Fibrosis | Michael R. Blackburn, PhD The Role of Macrophages in Fibrosis | Michael R. Blackburn, PhD
professional_friday_1355_Olman_G-Summit-2015 professional_friday_1355_Olman_G-Summit-2015
professional_friday_1335_Mora_G-Summit-2015 professional_friday_1335_Mora_G-Summit-2015
2nd Place: Justin Oldham, TOLLIP, MUC5B and the Response to N-acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis 2nd Place: Justin Oldham, TOLLIP, MUC5B and the Response to N-acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis
Question-and-Answer Period and Panel Discussion | Leaders: Ivan O. Rosas, MD; Christine Kim Garcia, MD, PhD Question-and-Answer Period and Panel Discussion | Leaders: Ivan O. Rosas, MD; Christine Kim Garcia, MD, PhD
professional_friday_1140_Martinez_G-Summit-2015 professional_friday_1140_Martinez_G-Summit-2015
professional_friday_1120_Kaminski_G-Summit-2015 professional_friday_1120_Kaminski_G-Summit-2015
Genetics of Pulmonary Fibrosis | Christine Kim Garcia, MD, PhD Genetics of Pulmonary Fibrosis | Christine Kim Garcia, MD, PhD
An Overview of Personalized Medicine for Pulmonary Fibrosis | Ivan O. Rosas, MD An Overview of Personalized Medicine for Pulmonary Fibrosis | Ivan O. Rosas, MD
1st Place: Robert Guzy, Fibroblast-specific FGF signaling in bleomycin-induced pulmonary fibrosis 1st Place: Robert Guzy, Fibroblast-specific FGF signaling in bleomycin-induced pulmonary fibrosis
The Future of Drug Development in Pulmonary Fibrosis — A Regulatory Perspective | Janet Woodcock, MD The Future of Drug Development in Pulmonary Fibrosis — A Regulatory Perspective | Janet Woodcock, MD
Familial PF Webinar_10.2015 Familial PF Webinar_10.2015
SGLN Training Webinar 1_October 2015 SGLN Training Webinar 1_October 2015
PF Advocacy Webinar_9.2.15 PF Advocacy Webinar_9.2.15
IMG_1308 (1) IMG_1308 (1)
IPF Treatment Guidelines_8.19.15 IPF Treatment Guidelines_8.19.15
AskADoc_6.10.15 AskADoc_6.10.15
Palliative Webinar_4.15.15 Palliative Webinar_4.15.15
Ask a Doc_3.18.15 Ask a Doc_3.18.15
Pulmonary Hypertension_3.11.15 Pulmonary Hypertension_3.11.15
Occupational and Environmental PF Webinar_2.4.15 Occupational and Environmental PF Webinar_2.4.15
Coping with PF_3 Coping with PF_3
Lung Transplantation_1.14.15 Lung Transplantation_1.14.15
Coping with PF Webinar_12.10.14 Coping with PF Webinar_12.10.14
Autoimmune-Related PF_11.12.14 Autoimmune-Related PF_11.12.14
Truth-Telling Webinar_10.22.14 Truth-Telling Webinar_10.22.14
Edited Leiberman Live Edited Leiberman Live
Drug Development Webinar_9.17.14 Drug Development Webinar_9.17.14
Supplemental Oxygen Webinar_9.3.14 Supplemental Oxygen Webinar_9.3.14
Caregiving 101 Caregiving 101
July 23 Webinar: Pulmonary Rehab, Support Groups & Q+A July 23 Webinar: Pulmonary Rehab, Support Groups & Q+A
July 23 Webinar: Intro & PFF Ambassador Story July 23 Webinar: Intro & PFF Ambassador Story
ipf consensus guidelines_7.16.14 ipf consensus guidelines_7.16.14
barcelona-talk-09-SP barcelona-talk-09-SP
barcelona-talk-09 barcelona-talk-09
barcelona-talk-08 barcelona-talk-08
barcelona-talk-07 barcelona-talk-07
barcelona-talk-06 barcelona-talk-06
barcelona-talk-06-SP barcelona-talk-06-SP
barcelona-talk-04 barcelona-talk-04
barcelona-talk-05 barcelona-talk-05
barcelona-talk-01 barcelona-talk-01
barcelona-talk-03 barcelona-talk-03
barcelona-talk-02 barcelona-talk-02
barcelona-talk-01-SP barcelona-talk-01-SP
Ask a Doc_5.28.14_final Ask a Doc_5.28.14_final
Webinar_5.14.14_final Webinar_5.14.14_final
Awareness-2012-Int-SP-08 Awareness-2012-Int-SP-08
Awareness-2012-Int-SP-06 Awareness-2012-Int-SP-06
Awareness-2012-Int-SP-07 Awareness-2012-Int-SP-07
Awareness-2012-Int-SP-03 Awareness-2012-Int-SP-03
Awareness-2012-Int-SP-02 Awareness-2012-Int-SP-02
Awareness-2012-Int-SP-09 Awareness-2012-Int-SP-09
Awareness-2012-Int-SP-04 Awareness-2012-Int-SP-04
Awareness-2012-Int-SP-01 Awareness-2012-Int-SP-01
Awareness-2012-Int-SP-05 Awareness-2012-Int-SP-05
Awareness-2012-Int-IT-08 Awareness-2012-Int-IT-08
Awareness-2012-Int-IT-01 Awareness-2012-Int-IT-01
Awareness-2012-Int-IT-02 Awareness-2012-Int-IT-02
Awareness-2012-Int-IT-04 Awareness-2012-Int-IT-04
Awareness-2012-Int-IT-06 Awareness-2012-Int-IT-06
Awareness-2012-Int-IT-05 Awareness-2012-Int-IT-05
Awareness-2012-Int-IT-09 Awareness-2012-Int-IT-09
Awareness-2012-Int-IT-07 Awareness-2012-Int-IT-07
Awareness-2012-Int-IT-03 Awareness-2012-Int-IT-03
Awareness-2012-Int-DE-07 Awareness-2012-Int-DE-07
Awareness-2012-Int-DE-09 Awareness-2012-Int-DE-09
Awareness-2012-Int-DE-08 Awareness-2012-Int-DE-08
Awareness-2012-Int-FR-08 Awareness-2012-Int-FR-08
Load more